27374-25-0,CAS 27374-25-0

Product Name:(1-ethoxycyclopropoxy)trimethylsilane

IUPAC Name:(1-ethoxycyclopropoxy)trimethylsilane

Packing Unit	Available Stock	Price($)
CM111264-10g	in stock	ȋǺƚ
CM111264-50g	in stock	Ǡşş

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:27374-25-0; Molecular Formula:C8H18O2Si; Melting Point:-; Smiles Code:C[Si](C)(OC1(OCC)CC1)C; Density:

: Catalog Number:CM111264; Molecular Weight:174.32; Boiling Point:; MDL No:MFCD00074986; Storage:

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Silane Compounds; Silanes are a series of silicon substitutes for carbon alkanes, which consisting of multiple silicon atoms linked to each other as the main chain and hydrogen atoms or other chemical elements linked with the main chain. Silanes are versatile chemicals used in the modification of SPR sensor surfaces. In particular, the silane molecules, such as 3-mercaptopropyl trimethoxy silane, are convenient for use as linkers in surface modification of SPR sensors.

: JNT-517; Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.